ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Abstract Text:

Jennifer A Mertz,Ryuji Kobayashi,Jaquelin P Dudley,

Type B leukemogenic virus (TBLV), a mouse mammary tumor virus (MMTV) variant, often induces T-cell leukemias and lymphomas by c-myc activation following viral DNA integration. Transfection assays using a c-myc reporter plasmid indicated that the TBLV long terminal repeat (LTR) enhancer is necessary for T-cell-specific increases in basal reporter activity. The sequence requirements for this effect were studied using mutations of the 62-bp enhancer region in an MMTV LTR reporter vector. Deletion of a nuclear factor A-binding site dramatically reduced reporter activity in Jurkat T cells. However, a 41-bp enhancer missing the RUNX1 site still retained minimal enhancer function. DNA affinity purification using a TBLV enhancer oligomer containing the RUNX1 binding site followed by mass spectrometry resulted in the identification of ALY. Subsequent experiments focused on the reconstitution of enhancer activity in epithelial cells. ALY overexpression synergized with RUNX1B on TBLV enhancer activity, and synergism required the RUNX1B-binding site. A predicted c-Myb binding site in the enhancer was confirmed after c-myb overexpression elevated TBLV LTR reporter activity, and overexpression of c-Myb and RUNX1B together showed additive effects on reporter gene levels. ALY also synergized with c-Myb, and coimmunoprecipitation experiments demonstrated an interaction between ALY and c-Myb. These experiments suggest a central role for ALY in T-cell enhancer function and oncogene activation.

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Publishing Authors By Initials

JA Mertz,R Kobayashi,JP Dudley,

For similar genetic processes: gene expression regulation: up-regulation research abstracts see: genetic processes: gene expression regulation: up-regulation research

PUBMED ID PMID:

MEDLINE DATE:

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of virology

VOLUME: 81

Page Numbers: 3503-13

Journal Abbreviation: J. Virol.

ISSN: 0022-538X

DAY: 17

MONTH: 01

YEAR: 2007

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 113724

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Keywords Mesh Terms:

KEYWORDS: Up-Regulation

MESH TERMS: metabolism

Chemical & Substance for Abstract: ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Information

Substance Name: Transcription Factors

Registry Number: 0

Grant and Affiliation Information for ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.

AFFILIATION: Section of Molecular Genetics and Microbiology, University of Texas at Austin, One University Station, A5000 24th Street and Speedway, ESB 226, Austin, TX 78712-0162, USA.

Country: United States

AGENCY: United States NCI

GRANT: R01 CA 116813

ACRONYM: CA

MEDLINETA: J Virol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer Related Publications

• 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation.
• A Boisen reverie.
• A sodium channel pore mutation causing Brugada syndrome.
• A tandem carbanion addition/carbon-carbon bond cleavage yields alkynyl ketones.
• A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling.
• ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.
• Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation.
• Characterization of green fluorescent protein-expressing retinal cells in CD 44-transgenic mice.
• Determination of gallium in biological materials.
• Diabetic-associated stillbirth: incidence, pathophysiology, and prevention.
• Early determinants of H2O2-induced endothelial dysfunction.
• Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.
• Generation and characterization of 0.6-THz polarization domain-wall trains in an ultralow-birefringence spun fiber.
• Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel.
• Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
• Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation.
• Muscle pain prophylaxis.
• Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias.
• Optimization of apodization functions in terahertz transient spectrometry.
• Oxidative stress markers are associated with persistent atrial fibrillation.
• Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model.
• Physiological Responses of Combining Electrical Stimulation of the Thighs with Voluntary Arm Exercise on the NuStep(R): 2549: Board #96 June 2 9:30 AM - 11:00 AM.
• Post stroke fatigue--where is the evidence to guide practice?
• Prediction of Atrial Fibrillation following Cardiac Surgery using Rough Set Derived Rules.
• Skeletal muscle atrophy and increased intramuscular fat after incomplete spinal cord injury.
• Skin bacteria and Op Site((R)) chest dressings.
• Sustaining evidence-based practice for young people who self-harm: a 4-year follow-up.
• Synthesis of benzyl esters using 2-benzyloxy-1-methylpyridinium triflate.
• Use of trifluoroacetic acid to quantify small, polar compounds in rat plasma during discovery-phase pharmacokinetic evaluation.
• Variable-frequency-train stimulation of skeletal muscle after spinal cord injury.